SIRT1 Restores Autophagic Flux to Attenuate Podocyte Injury in Experimental Membranous Nephropathy

Technical Summary: SIRT1 Restores Autophagic Flux to Attenuate Podocyte Injury in Experimental Membranous Nephropathy

Problem Statement
Membranous nephropathy (MN) is a primary cause of adult nephrotic syndrome, characterized by subepithelial immune deposits and subsequent podocyte injury. While the pathogenesis involves autoantibodies against podocyte antigens (e.g., PLA2R, THSD7A), a critical mechanism of injury is the deposition of the sublytic complement membrane attack complex (C5b-9). This deposition disrupts autophagic flux by impairing lysosomal acidification and autophagosome-lysosome fusion, leading to cellular damage and proteinuria. Current therapies often rely on immunosuppression, which may not address these non-immunological injury mechanisms. The specific role of Sirtuin 1 (SIRT1), an NAD⁺-dependent deacetylase known to regulate cellular homeostasis and autophagy, in MN-related podocyte injury remains undefined.

Methodology
The study employed a dual-model approach combining in vivo and in vitro systems to investigate SIRT1's function:

• Animal Models:
  • Passive Heymann Nephritis (PHN) Rats: Male Sprague-Dawley rats were induced with PHN using sheep anti-rat Fx1A antiserum. Animals were treated with Resveratrol (RSV, a SIRT1 activator) or FK506 (an immunosuppressant control). Tissue and blood were collected at day 50 post-modeling.
  • Genetic Mouse Model: Podocyte-specific SIRT1 knockout mice (SIRT1ΔPod) were generated on a C57BL/6J background to assess the cell-autonomous role of SIRT1 in aged mice.
• Cell Models: Immortalized mouse podocytes (MPC-5) were subjected to complement injury using zymosan-activated serum (ZAS) to simulate sublytic C5b-9 attack. Cells were pretreated with RSV or SRT1720 (a specific SIRT1 agonist).
• Assessments:
  • Physiological/Biochemical: 24-hour urinary protein, serum albumin, lipids, creatinine, and lactate dehydrogenase (LDH) release.
  • Histopathology: Light microscopy (H&E, PAS, PASM), transmission electron microscopy (EM) for foot process effacement and lysosomal morphology, and immunofluorescence for protein deposition (IgG, C3, C5b-9) and markers (Nephrin, Podocin, Synaptopodin).
  • Molecular Analysis: Western blotting and immunofluorescence for autophagy markers (ATG5, ATG7, Beclin-1, LC3B, p62) and SIRT1 activity assays.
  • Mechanistic Studies: Co-immunoprecipitation (Co-IP) to verify interactions between SIRT1 and target proteins (ATG7, Beclin-1, Cortactin/CTTN). Colocalization studies (LC3-LAMP1, Ub-LAMP1, CTTN-LAMP1) were used to assess autophagosome-lysosome fusion.

Key Contributions and Results

1. Therapeutic Efficacy of SIRT1 Activation: In PHN rats, pharmacological activation of SIRT1 (via RSV) significantly reduced 24-hour urinary protein excretion, elevated serum albumin, and improved lipid profiles compared to the untreated model group. Histologically, RSV treatment attenuated glomerular basement membrane (GBM) thickening, reduced foot process effacement, and decreased glomerular deposition of IgG, C3, and C5b-9. Notably, RSV treatment partially restored the disparity between glomerular and tubular SIRT1 fluorescence intensity, whereas glomerular SIRT1 fluorescence in the FK506 group remained significantly weaker than tubular SIRT1.
2. Protection Against Complement-Mediated Injury: In podocytes, SIRT1 agonists (RSV and SRT1720) significantly attenuated complement-induced LDH release and cytoskeletal disruption. They restored SIRT1 activity, which was suppressed by ZAS injury. Podocin expression in both RSV and SRT1720 groups was significantly lower than in the blank control group but significantly higher than in the model group. Synaptopodin expression was significantly higher in both the RSV and SRT1720 groups compared to the model group.
3. Restoration of Autophagic Flux: The study identified that C5b-9 injury in MN leads to an accumulation of autophagosomes and p62, indicating a blockade in autophagic flux rather than a lack of initiation. SIRT1 activation resolved this blockade. While autophagy initiation markers (ATG7, Beclin-1) were elevated in the injury model, SIRT1 activation specifically promoted the fusion of autophagosomes with lysosomes. This was evidenced by improved colocalization of LC3 with LAMP1 and reduced accumulation of p62.
4. Mechanism of Action via Deacetylation: Co-immunoprecipitation assays confirmed that SIRT1 physically interacts with ATG7, Beclin-1, and Cortactin (CTTN). The study posits that SIRT1-mediated deacetylation of CTTN is a critical step in restoring the fusion capability of autophagosomes and lysosomes. The authors note that while SIRT1 is known to deacetylate ATG7 and Beclin-1 in other contexts, the specific reduction of these proteins observed in their model contrasts with mainstream findings, leading them to emphasize the role of CTTN deacetylation in promoting fusion as the primary mechanism in this context.
5. Role of Endogenous SIRT1: In aged SIRT1ΔPod mice, the absence of podocyte-specific SIRT1 resulted in increased urinary albumin-to-creatinine ratio (UACR) and hypercholesterolemia, despite the absence of overt structural damage or immune deposition. This suggests that SIRT1 is essential for the functional maintenance of podocytes.

Significance and Claims
The paper claims to establish a novel therapeutic axis for MN that is independent of classical immunosuppression. The primary significance lies in demonstrating that SIRT1 protects podocytes not merely by inducing autophagy, but by reprogramming a dysfunctional autophagic process. Specifically, the authors argue that C5b-9 attack triggers a compensatory autophagic response that becomes pathologically blocked at the fusion stage ("autophagic constipation"). SIRT1 activation rectifies this specific defect by promoting autophagosome-lysosome fusion through the deacetylation of CTTN and other regulators.

The study positions SIRT1 as a critical modulator of autophagic quality and flow, offering a potential non-immunosuppressive strategy to ameliorate podocyte injury and proteinuria in membranous nephropathy. The authors acknowledge limitations, including the preclinical nature of the PHN model and the need for future validation in human biopsy samples and the use of more specific SIRT1 activation methods (e.g., NAD+ precursors) to confirm these findings.